- Home
- TRC vs VSTM Comparison
TRC vs VSTM Comparison
Compare TRC & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- VSTM
- Stock Information
- Founded
- TRC 1843
- VSTM 2010
- Country
- TRC United States
- VSTM United States
- Employees
- TRC N/A
- VSTM N/A
- Industry
- TRC Real Estate
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- TRC Finance
- VSTM Health Care
- Exchange
- TRC Nasdaq
- VSTM Nasdaq
- Market Cap
- TRC 440.9M
- VSTM 425.9M
- IPO Year
- TRC N/A
- VSTM 2012
- Fundamental
- Price
- TRC $18.65
- VSTM $4.69
- Analyst Decision
- TRC
- VSTM Strong Buy
- Analyst Count
- TRC 0
- VSTM 9
- Target Price
- TRC N/A
- VSTM $12.63
- AVG Volume (30 Days)
- TRC 98.7K
- VSTM 2.5M
- Earning Date
- TRC 08-05-2025
- VSTM 08-07-2025
- Dividend Yield
- TRC N/A
- VSTM N/A
- EPS Growth
- TRC 298.28
- VSTM N/A
- EPS
- TRC 0.08
- VSTM N/A
- Revenue
- TRC $42,689,000.00
- VSTM $10,000,000.00
- Revenue This Year
- TRC $0.64
- VSTM $129.06
- Revenue Next Year
- TRC N/A
- VSTM $306.32
- P/E Ratio
- TRC $230.25
- VSTM N/A
- Revenue Growth
- TRC 7.04
- VSTM N/A
- 52 Week Low
- TRC $14.71
- VSTM $2.10
- 52 Week High
- TRC $19.82
- VSTM $9.10
- Technical
- Relative Strength Index (RSI)
- TRC 72.42
- VSTM 39.03
- Support Level
- TRC $17.47
- VSTM $4.60
- Resistance Level
- TRC $18.02
- VSTM $4.90
- Average True Range (ATR)
- TRC 0.38
- VSTM 0.32
- MACD
- TRC 0.15
- VSTM 0.10
- Stochastic Oscillator
- TRC 98.00
- VSTM 64.29
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.